Pseudomonas aeruginosa and the host pulmonary immune response

Expert Review of Respiratory Medicine

Volumn 1, Issue 1, 2007, Pages 121-137

  Dubin, Patricia J ^a   Kolls, Jay K ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

antigen presenting cell; biofilm; CXC chemokines; cystic fibrosis; IL 1; IL 17; IL 23; immunoglobulin; neutrophil; vaccine

Indexed keywords

EID: 85002974027     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.1.121     Document Type: Article

References (242)

1. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J. Med. Virol. 78 (6), 829–838 (2006).
2. Petersen NT, Hoiby N, Mordhorst CH et al. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma – possible synergism with Pseudomonas aeruginosa. Acta Paediatr. Scand. 70 (5), 623–628 (1981).
3. Lowbury EJ, Thom BT, Lilly HA, Babb JR, Whittall K. Sources of infection with Pseudomonas aeruginosa in patients with tracheostomy. J. Med. Microbiol. 3 (1), 39–56 (1970).
4. Perea EJ, Criado A, Moreno M, Avello F. Mechanical ventilators as vehicles of infection. Acta Anaesthesiol. Scand. 19 (3), 180–186 (1975).
5. Still J, Newton T, Friedman B et al. Experience with pneumonia in acutely burned patients requiring ventilator support. Am. Surg. 66 (2), 206–209 (2000).
6. Zawacki BE, Jung RC, Joyce J, Rincon E. Smoke, burns, and the natural history of inhalation injury in fire victims: a correlation of experimental and clinical data. Ann. Surg. 185 (1), 100–110 (1977).
7. Petdachai W. Ventilator-associated pneumonia in a newborn intensive care unit. Southeast Asian J. Trop. Med. Public Health 35 (3), 724–729 (2004).
8. Zawacki A, O’Rourke E, Potter-Bynoe G et al. An outbreak of Pseudomonas aeruginosa pneumonia and bloodstream infection associated with intermittent otitis externa in a healthcare worker. Infect. Control Hosp. Epidemiol. 25 (12), 1083–1089 (2004).
9. Bonifacio SL, Kitterman JA, Ursell PC. Pseudomonas pneumonia in infants: an autopsy study. Hum. Pathol. 34 (9), 929–938 (2003).
10. Usukura Y, Igarashi T. Examination of severe, hospital acquired infections affecting extremely low birthweight (ELBW) infants. Pediatr. Int. 45 (2), 230–232 (2003).
11. Burns JL, Gibson RL, McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183 (3), 444–452 (2001).
12. Kosorok MR, Zeng L, West SE et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr. Pulmonol. 32 (4), 277–287 (2001).
13. Machen TE. Innate immune response in CF airway epithelia: hyperinflammatory? Am. J. Physiol. Cell Physiol. 291 (2), C218 –C230 (2006).
14. Moroni M, Franzetti F. Bacterial pneumonia in adult patients with HIV infection. J. Chemother. 7 (4), 292–306 (1995).
15. Franzetti F, Cernuschi M, Esposito R, Moroni M. Pseudomonas infections in patients with AIDS and AIDS-related complex. J. Intern. Med. 231 (4), 437–443 (1992).
16. Taylor IK, Coker RJ, Clarke J et al. Pulmonary complications of HIV disease: 10 year retrospective evaluation of yields from bronchoalveolar lavage, 1983–93. Thorax 50 (12), 1240–1245 (1995).
17. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 113 (5), 1225–1229 (1998).
18. Manfredi R, Nanetti A, Ferri M, Chiodo F. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur. J. Epidemiol. 16 (2), 111–118 (2000).
19. Rosenberg AL, Seneff MG, Atiyeh L et al. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit. Care Med. 29 (3), 548–556 (2001).
20. Tumbarello M, Tacconelli E, Caponera S, Cauda R, Ortona L. The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. J. Infect. 31 (2), 123–131 (1995).
21. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 19 (12), 915–925 (2000).
22. Bodey GP. Pseudomonas aeruginosa infections in cancer patients: have they gone away? Curr. Opin. Infect. Dis. 14 (4), 403–407 (2001).
23. Carratala J, Roson B, Fernandez-Sevilla A, Alcaide F, Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch. Intern. Med. 158 (8), 868–872 (1998).
24. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med. 145 (9), 1621–1629 (1985).
25. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin. Microbiol. Infect. 11 (Suppl. 4) 17–32 (2005).
26. Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch. Intern. Med. 156 (18), 2121–2126 (1996).
27. Kang CI, Kim SH, Kim HB et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37 (6), 745–751 (2003).
28. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109 (4), 1019–1029 (1996).
29. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17 (1), 47–56 (2002).
30. Canton R, Lode H, Graninger W, Milkovich G. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Int. J. Antimicrob. Agents 28 (Suppl. 2), S115 –S127 (2006).
31. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 113 (6), 1542–1548 (1998).
32. Marshall BC, Carroll KC. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis. Semin. Respir. Infect. 6 (1), 11–18 (1991).
33. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34 (2), 91–100 (2002).
34. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother. 43 (Suppl. A), 97–105 (1999).
35. Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch. Intern. Med. 165 (8), 891–897 (2005).
36. Afessa B, Green B. Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (pulmonary complications ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 118 (1), 138–145 (2000).
37. Vidal F, Mensa J, Martinez JA et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 18 (7), 473–477 (1999).
38. Domingo P, Ferre A, Baraldes MA, Ris J, Sanchez F. Pseudomonas aeruginosa bronchopulmonary infection in patients with AIDS, with emphasis on relapsing infection. Eur. Respir. J. 12 (1), 107–112 (1998).
39. Speert DP, Campbell ME, Henry DA et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia Canada. Am. J. Respir. Crit. Care Med. 166 (7), 988–993 (2002).
40. Campana S, Taccetti G, Ravenni N et al. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J. Cyst. Fibros. 3 (3), 159–163 (2004).
41. Boucher JC, Schurr MJ, Deretic V. Dual regulation of mucoidy in Pseudomonas aeruginosa and σ factor antagonism. Mol. Microbiol. 36 (2), 341–351 (2000).
42. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. USA 103 (22), 8487–8492 (2006).
43. Chugani S, Greenberg EP. The influence of human respiratory epithelia on Pseudomonas aeruginosa gene expression. Microb. Pathog. 42 (1), 29–35 (2007).
44. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416 (6882), 740–743 (2002).
45. Head NE, Yu H. Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity. Infect. Immun. 72 (1), 133–144 (2004).
46. Ernst RK, Hajjar AM, Tsai JH et al. Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4. J. Endotoxin Res. 9 (6), 395–400 (2003).
47. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34 (5), 1129–1135 (1996).
48. Ernst RK, Yi EC, Guo L et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286 (5444), 1561–1565 (1999).
49. Ranes JL, Gordon SM, Chen P et al. Predictors of long-term mortality in patients with ventilator-associated pneumonia. Am. J. Med. 119 (10), E13 –E19 (2006).
50. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 120 (2), 555–561 (2001).
51. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 43 (Suppl. 2) S43 –S48 (2006).
52. Gales AC, Sader HH, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997–2000). Diagn. Microbiol. Infect. Dis. 44 (3), 301–311 (2002).
53. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. 32 (Suppl. 2) S146 –S155 (2001).
54. Zavascki AP, Barth AL, Fernandes JF et al. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective observational study. Crit. Care 10 (4), R114 (2006).
55. Nseir S, Di Pompeo C, Cavestri B et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit. Care Med. 34 (12), 2959–2966 (2006).
56. Combes A, Luyt CE, Trouillet JL. Impact of antibiotic-resistant bacteria on the outcome of ventilator-associated pneumonia. Semin. Respir. Crit. Care Med. 27 (1), 23–28 (2006).
57. Danchaivijitr S, Dhiraputra C, Rongrungruang Y, Worajitr M, Jintanothaitavorn D. Antimicrobial susceptibility of community and hospital acquired bacteria. J. Med. Assoc. Thai. 88 (Suppl. 10), S14 –S25 (2005).
58. Macia MD, Blanquer D, Togores B et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49 (8), 3382–3386 (2005).
59. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288 (5469), 1251–1254 (2000).
60. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32 (8), 470–485 (2004).
61. Diaz E, Rodriguez AH, Rello J. Ventilator-associated pneumonia: issues related to the artificial airway. Respir. Care 50 (7), 900–906; discussion 906–909 (2005).
62. Akca O, Koltka K, Uzel S et al. Risk factors for early-onset, ventilator-associated pneumonia in critical care patients: selected multiresistant versus nonresistant bacteria. Anesthesiology 93 (3), 638–645 (2000).
63. Adair CG, Gorman SP, Feron BM et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med. 25 (10), 1072–1076 (1999).
64. Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit. Care Med. 32 (6), 1396–1405 (2004).
65. Ma J, Hu B, He L. Gastric colonization and its effect on pathogenesis of nosocomial pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 22 (2), 104–107 (1999).
66. Mitsushima H, Oishi K, Nagao T et al. Acid aspiration induces bacterial pneumonia by enhanced bacterial adherence in mice. Microb. Pathog. 33 (5), 203–210 (2002).
67. Pawar M, Mehta Y, Khurana P et al. Ventilator-associated pneumonia: incidence, risk factors, outcome, and microbiology. J. Cardiothorac. Vasc. Anesth. 17 (1), 22–28 (2003).
68. Hauser AR, Cobb E, Bodi M et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30 (3), 521–528 (2002).
69. Roy-Burman A, Savel RH, Racine S et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183 (12), 1767–1774 (2001).
70. Maybauer MO, Maybauer DM, Traber LD et al. Gentamicin improves hemodynamics in ovine septic shock after smoke inhalation injury. Shock 24 (3), 226–231 (2005).
71. Linares HA. A report of 115 consecutive autopsies in burned children: 1966–80. Burns Incl. Therm. Inj. 8 (4), 263–270 (1982).
72. Aduen JF, Hellinger WC, Kramer DJ et al. Spectrum of pneumonia in the current era of liver transplantation and its effect on survival. Mayo Clin. Proc. 80 (10), 1303–1306 (2005).
73. Franzetti F, Grassini A, Piazza M et al. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 34 (1), 9–16 (2006).
74. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116 (1), 40–46 (1999).
75. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 12 (1), 81–87 (2007).
76. Winnie GB, Cowan RG. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr. Pulmonol. 10 (2), 92–100 (1991).
77. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 9 (6), 492–497 (2003).
78. Pamukcu A, Bush A, Buchdahl R. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 19 (1), 10–15 (1995).
79. Potts SB, Roggli VL, Spock A. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatr. Pathol. Lab. Med. 15 (5), 707–721 (1995).
80. Baltimore RS, Christie CD, Smith GJ. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am. Rev. Respir. Dis. 140 (6), 1650–1661 (1989).
81. Shapiro ED, Milmoe GJ, Wald ER, Rodnan JB, Bowen AD. Bacteriology of the maxillary sinuses in patients with cystic fibrosis. J. Infect. Dis. 146 (5), 589–593 (1982).
82. Davis PB, di Sant’Agnese PA. Diagnosis and treatment of cystic fibrosis. An update. Chest 85 (6), 802–809 (1984).
83. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Intern. Med. 261 (1), 5–16 (2007).
84. Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol. Cell 2 (3), 397–403 (1998).
85. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85 (2), 229–236 (1996).
86. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc. Natl Acad. Sci. USA 94 (22), 12088–12093 (1997).
87. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc. Natl Acad. Sci. USA 97 (16), 8822–8828 (2000).
88. Schroeder TH, Lee MM, Yacono PW et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-κB translocation. Proc. Natl Acad. Sci. USA 99 (10), 6907–6912 (2002).
89. Kowalski MP, Pier GB. Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J. Immunol. 172 (1), 418–425 (2004).
90. Bryan R, Kube D, Perez A, Davis P, Prince A. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am. J. Respir. Cell. Mol. Biol. 19 (2), 269–277 (1998).
91. de Bentzmann S, Roger P, Dupuit F et al. Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect. Immun. 64 (5), 1582–1588 (1996).
92. Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J. Clin. Invest. 92 (4), 1875–1880 (1993).
93. Darling KE, Dewar A, Evans TJ. Role of the cystic fibrosis transmembrane conductance regulator in internalization of Pseudomonas aeruginosa by polarized respiratory epithelial cells. Cell. Microbiol. 6 (6), 521–533 (2004).
94. Venkatakrishnan A, Stecenko AA, King G et al. Exaggerated activation of nuclear factor-κB and altered IκB-β processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol. 23 (3), 396–403 (2000).
95. Tirouvanziam R, de Bentzmann S, Hubeau C et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am. J. Respir. Cell. Mol. Biol. 23 (2), 121–127 (2000).
96. Tabary O, Escotte S, Couetil JP et al. Relationship between IκBα deficiency NFκB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Arch. 443 (Suppl. 1) S40 –S44 (2001).
97. Weber AJ, Soong G, Bryan R, Saba S, Prince A. Activation of NF-κB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am. J. Physiol. Lung Cell. Mol. Physiol. 281 (1), L71 –L78 (2001).
98. Karp CL, Flick LM, Yang R, Uddin J, Petasis NA. Cystic fibrosis and lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73 (3–4), 263–270 (2005).
99. Scharfman A, Van Brussel E, Houdret N, Lamblin G, Roussel P. Interactions between glycoconjugates from human respiratory airways and Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 154 (4 Pt 2), S163 –S169 (1996).
100. DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J. Clin. Invest. 96 (5), 2204–2210 (1995).
101. Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J. Clin. Invest. 113 (10), 1482–1489 (2004).
102. Watts TH, Sastry PA, Hodges RS, Paranchych W. Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili. Infect. Immun. 42 (1), 113–121 (1983).
103. Ramphal R, Sadoff JC, Pyle M, Silipigni JD. Role of pili in the adherence of Pseudomonas aeruginosa to injured tracheal epithelium. Infect. Immun. 44 (1), 38–40 (1984).
104. Feldman M, Bryan R, Rajan S et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 66 (1), 43–51 (1998).
105. Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect. Immun. 73 (11), 7151–7160 (2005).
106. Skerrett SJ, Wilson CB, Liggitt HD, Hajjar AM. Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell. Mol. Physiol. 292 (1), L312 –L322 (2007).
107. Prince A. Flagellar activation of epithelial signaling. Am. J. Respir. Cell. Mol. Biol. 34 (5), 548–551 (2006).
108. Jyot J, Sonawane A, Wu W, Ramphal R. Genetic mechanisms involved in the repression of flagellar assembly by Pseudomonas aeruginosa in human mucus. Mol. Microbiol. 63 (4), 1026–1038 (2007).
109. Berlutti F, Morea C, Battistoni A et al. Iron availability influences aggregation, biofilm, adhesion and invasion of Pseudomonas aeruginosa and Burkholderia cenocepacia. Int. J. Immunopathol. Pharmacol. 18 (4), 661–670 (2005).
110. Walker TS, Tomlin KL, Worthen GS et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun. 73 (6), 3693–3701 (2005).
111. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19 (1), 83–88 (2007).
112. Spangenberg C, Heuer T, Burger C, Tummler B. Genetic diversity of flagellins of Pseudomonas aeruginosa. FEBS Lett. 396 (2–3), 213–217 (1996).
113. Doring G, Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst. Mitt. 98, 338–344 (1997).
114. Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. 72 (12), 6969–6977 (2004).
115. Ader F, Le Berre R, Faure K et al. Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system. Infect. Immun. 73 (7), 4263–4271 (2005).
116. Vance RE, Rietsch A, Mekalanos JJ. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect. Immun. 73 (3), 1706–1713 (2005).
117. Davies DG, Parsek MR, Pearson JP et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280 (5361), 295–298 (1998).
118. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28 (2), 546–556 (1980).
119. Hoiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J. Cyst. Fibros. 1 (4), 249–254 (2002).
120. Smith RS, Harris SG, Phipps R, Iglewski B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)homoserine lactone contributes to virulence and induces inflammation in vivo. J. Bacteriol. 184 (4), 1132–1139 (2002).
121. Smith RS, Fedyk ER, Springer TA et al. IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-κB and activator protein-2. J. Immunol. 167 (1), 366–374 (2001).
122. Tateda K, Ishii Y, Horikawa M et al. The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect. Immun. 71 (10), 5785–5793 (2003).
123. Tateda K, Ishii Y, Matsumoto T et al. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J. Infect. Chemother. 6 (1), 1–7 (2000).
124. Tateda K, Comte R, Pechere JC et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45 (6), 1930–1933 (2001).
125. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (13), 1749–1756 (2003).
126. Takase H, Nitanai H, Hoshino K, Otani T. Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect. Immun. 68 (4), 1834–1839 (2000).
127. Visca P, Colotti G, Serino L et al. Metal regulation of siderophore synthesis in Pseudomonas aeruginosa and functional effects of siderophore-metal complexes. Appl. Environ. Microbiol. 58 (9), 2886–2893 (1992).
128. Meyer JM, Neely A, Stintzi A, Georges C, Holder IA. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect. Immun. 64 (2), 518–523 (1996).
129. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3 (4), 354–359 (2002).
130. Ernst RK, Adams KN, Moskowitz SM et al. The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway. J. Bacteriol. 188 (1), 191–201 (2006).
131. Augustin DK, Song Y, Baek MS et al. Presence or absence of lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa. J. Bacteriol. 189 (6), 2203–2209 (2007).
132. Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med. Mal. Infect. 36 (2), 78–91 (2006).
133. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 171 (11), 1209–1223 (2005).
134. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can’t they clear the infection? Respir. Res. 4, 8 (2003).
135. Green SK, Schroth MN, Cho JJ, Kominos SK, Vitanza-jack VB. Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa. Appl. Microbiol. 28 (6), 987–991 (1974).
136. Vianelli N, Giannini MB, Quarti C et al. Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. Haematologica 91 (7), 983–985 (2006).
137. Bertrand B, Collet S, Eloy P, Rombaux P. Secondary ciliary dyskinesia in upper respiratory tract. Acta Otorhinolaryngol. Belg. 54 (3), 309–316 (2000).
138. Carson JL, Collier AM, Fernald GW, Hu SC. Microtubular discontinuities as acquired ciliary defects in airway epithelium of patients with chronic respiratory diseases. Ultrastruct. Pathol. 18 (3), 327–332 (1994).
139. Elkins MR, Robinson M, Rose BR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 354 (3), 229–240 (2006).
140. Matsui H, Verghese MW, Kesimer M et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J. Immunol. 175 (2), 1090–1099 (2005).
141. Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G. Antimicrobial peptides in the airway. Curr. Top. Microbiol. Immunol. 306, 153–182 (2006).
142. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol. Rev. 173, 27–38 (2000).
143. Grassme H, Kirschnek S, Riethmueller J et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 290 (5491), 527–530 (2000).
144. Hotchkiss RS, Dunne WM, Swanson PE et al. Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 294 (5548), 1783 (2001).
145. Rajan S, Cacalano G, Bryan R et al. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors. Am. J. Respir. Cell. Mol. Biol. 23 (3), 304–312 (2000).
146. Power MR, Peng Y, Maydanski E, Marshall JS, Lin TJ. The development of early host response to Pseudomonas aeruginosa lung infection is critically dependent on myeloid differentiation factor 88 in mice. J. Biol. Chem. 279 (47), 49315–49322 (2004).
147. Fritz JH, Girardin SE. How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J. Endotoxin Res. 11 (6), 390–394 (2005).
148. Fritz JH, Girardin SE, Fitting C et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 35 (8), 2459–2470 (2005).
149. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7 (12), 1250–1257 (2006).
150. Kooguchi K, Hashimoto S, Kobayashi A et al. Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect. Immun. 66 (7), 3164–3169 (1998).
151. Ojielo CI, Cooke K, Mancuso P et al. Defective phagocytosis and clearance of Pseudomonas aeruginosa in the lung following bone marrow transplantation. J. Immunol. 171 (8), 4416–4424 (2003).
152. Cheung DO, Halsey K, Speert DP. Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect. Immun. 68 (8), 4585–4592 (2000).
153. Sar B, Oishi K, Matsushima K, Nagatake T. Induction of interleukin 8 (IL-8) production by Pseudomonas nitrite reductase in human alveolar macrophages and epithelial cells. Microbiol. Immunol. 43 (5), 409–417 (1999).
154. Hashimoto S, Pittet JF, Hong K et al. Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections. Am. J. Physiol. 270 (5 Pt 1), L819 –L828 (1996).
155. Ballinger MN, Paine R III, Serezani CH et al. Role of granulocyte macrophage colony-stimulating factor during Gram-negative lung infection with Pseudomonas aeruginosa. Am. J. Respir. Cell. Mol. Biol. 34 (6), 766–774 (2006).
156. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. Med. 193 (1), 51–60 (2001).
157. Lambrecht BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur. Respir. J. 18 (4), 692–704 (2001).
158. Jahnsen FL, Strickland DH, Thomas JA et al. Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus. J. Immunol. 177 (9), 5861–5867 (2006).
159. Stumbles PA, Upham JW, Holt PG. Airway dendritic cells: co-ordinators of immunological homeostasis and immunity in the respiratory tract. APMIS 111 (7–8), 741–755 (2003).
160. Tsai WC, Strieter RM, Mehrad B et al. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect. Immun. 68 (7), 4289–4296 (2000).
161. Allen L, Dockrell DH, Pattery T et al. Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J. Immunol. 174 (6), 3643–3649 (2005).
162. Meyer KC, Zimmerman J. Neutrophil mediators Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J. Lab. Clin. Med. 121 (5), 654–661 (1993).
163. Ras GJ, Theron AJ, Anderson R et al. Enhanced release of elastase and oxidative inactivation of α-1-protease inhibitor by stimulated human neutrophils exposed to Pseudomonas aeruginosa pigment 1-hydroxyphenazine. J. Infect. Dis. 166 (3), 568–573 (1992).
164. Britigan BE, Edeker BL. Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation. J. Clin. Invest. 88 (4), 1092–1102 (1991).
165. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335–376 (2003).
166. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 15 (4), 396–401 (2003).
167. Travassos LH, Carneiro LA, Girardin SE et al. Nod1 participates in the innate immune response to Pseudomonas aeruginosa. J. Biol. Chem. 280 (44), 36714–36718 (2005).
168. Kravchenko VV, Kaufmann GF, Mathison JC et al. N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. J. Biol. Chem. 281 (39), 28822–28830 (2006).
169. Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE. Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. PLoS Pathog. 2 (3), E18 (2006).
170. Molofsky AB, Byrne BG, Whitfield NN et al. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J. Exp. Med. 203 (4), 1093–1104 (2006).
171. Schroeder TH, Zaidi T, Pier GB. Lack of adherence of clinical isolates of Pseudomonas aeruginosa to asialo-GM(1) on epithelial cells. Infect. Immun. 69 (2), 719–729 (2001).
172. Younger JG, Shankar-Sinha S, Mickiewicz M et al. Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am. J. Respir. Cell. Mol. Biol. 29 (4), 432–438 (2003).
173. Schiller NL, Joiner KA. Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect. Immun. 54 (3), 689–694 (1986).
174. Schiller NL, Hatch RA, Joiner KA. Complement activation and C3 binding by serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect. Immun. 57 (6), 1707–1713 (1989).
175. Sadikot RT, Zeng H, Yull FE et al. p47phox deficiency impairs NF-κB activation and host defense in Pseudomonas pneumonia. J. Immunol. 172 (3), 1801–1808 (2004).
176. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic. Biol. Med. 42 (2), 153–164 (2007).
177. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49 (6), 2276–2282 (2005).
178. Bouhafs RK, Samuelson A, Jarstrand C. Lipid peroxidation of lung surfactant due to reactive oxygen species released from phagocytes stimulated by bacteria from children with cystic fibrosis. Free Radic. Res. 37 (9), 909–917 (2003).
179. Bylund J, Burgess LA, Cescutti P, Ernst RK, Speert DP. Exopolysaccharides from Burkholderia cenocepacia inhibit neutrophil chemotaxis and scavenge reactive oxygen species. J. Biol. Chem. 281 (5), 2526–2532 (2006).
180. LeVine AM, Kurak KE, Bruno MD et al. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am. J. Respir. Cell. Mol. Biol. 19 (4), 700–708 (1998).
181. Alcorn JF, Wright JR. Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function. J. Biol. Chem. 279 (29), 30871–30879 (2004).
182. Wu Y, Xu Z, Henderson FC et al. Chronic Pseudomonas aeruginosa infection reduces surfactant levels by inhibiting its biosynthesis. Cell. Microbiol. 9 (4), 1062–1072 (2007).
183. Mariencheck WI, Alcorn JF, Palmer SM, Wright JR. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am. J. Respir. Cell. Mol. Biol. 28 (4), 528–537 (2003).
184. McCormack FX, Whitsett JA. The pulmonary collectins SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Invest. 109 (6), 707–712 (2002).
185. Gotte M, Echtermeyer F. Syndecan-1 as a regulator of chemokine function. Sci.World J. 3, 1327–1331 (2003).
186. Li, Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111 (5), 635–646 (2002).
187. Park PW, Pier GB, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411 (6833), 98–102 (2001).
188. Morissette C, Francoeur C, Darmond-Zwaig C, Gervais F. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect. Immun. 64 (12), 4984–4992 (1996).
189. Gosselin D, DeSanctis J, Boule M et al. Role of tumor necrosis factor α in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect. Immun. 63 (9), 3272–3278 (1995).
190. Schultz MJ, Rijneveld AW, Florquin S et al. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 282 (2), L285 –L290 (2002).
191. Yanagihara K, Tomono K, Kuroki M et al. Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa. Clin. Exp. Immunol. 122 (1), 67–71 (2000).
192. Harder J, Meyer-Hoffert U, Teran LM et al. Mucoid Pseudomonas aeruginosa TNF-α, and IL-1β, but not IL-6, induce human β-defensin-2 in respiratory epithelia. Am. J. Respir. Cell. Mol. Biol. 22 (6), 714–721 (2000).
193. Amura CR, Fontan PA, Sanjuan N et al. Tumor necrosis factor α plus interleukin 1β treatment protects granulocytopenic mice from Pseudomonas aeruginosa lung infection: role of an unusual inflammatory response. APMIS 103 (6), 447–459 (1995).
194. Jain-Vora S, LeVine AM, Chroneos Z et al. Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect. Immun. 66 (9), 4229–4236 (1998).
195. Song Z, Wu H, Ciofu O et al. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J. Med. Microbiol. 52 (Pt 9), 731–740 (2003).
196. Brazova J, Sediva A, Pospisilova D et al. Differential cytokine profile in children with cystic fibrosis. Clin. Immunol. 115 (2), 210–215 (2005).
197. Moser C, Johansen HK, Song Z et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 105 (11), 838–842 (1997).
198. Chmiel JF, Konstan MW, Saadane A et al. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am. J. Respir. Crit. Care Med. 165 (8), 1176–1181 (2002).
199. Chmiel JF, Konstan MW, Knesebeck JE et al. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am. J. Respir. Crit. Care Med. 160 (6), 2040–2047 (1999).
200. Sawa T, Corry DB, Gropper MA et al. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J. Immunol. 159 (6), 2858–2866 (1997).
201. Steinhauser ML, Hogaboam CM, Kunkel SL et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J. Immunol. 162 (1), 392–399 (1999).
202. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155 (4), 2222–2229 (1995).
203. Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 292 (2), L519 –L528 (2007).
204. Happel KI, Dubin PJ, Zheng M et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202 (6), 761–769 (2005).
205. Happel KI, Zheng M, Young E et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170 (9), 4432–4436 (2003).
206. McAllister F, Henry A, Kreindler JL et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-α and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immunol. 175 (1), 404–412 (2005).
207. Worgall S, Kikuchi T, Singh R et al. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells. Infect. Immun. 69 (7), 4521–4527 (2001).
208. Nieuwenhuis EE, Matsumoto T, Exley M et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 8 (6), 588–593 (2002).
209. Kinjo T, Nakamatsu M, Nakasone C et al. NKT cells play a limited role in the neutrophilic inflammatory responses and host defense to pulmonary infection with Pseudomonas aeruginosa. Microbes Infect. 8 (12–13), 2679–2685 (2006).
210. Moser C, Jensen PO, Pressler T et al. Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. APMIS 113 (6), 400–409 (2005).
211. Hartl D, Griese M, Kappler M et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J. Allergy Clin. Immunol. 117 (1), 204–211 (2006).
212. Lahat N, Rivlin J, Iancu TC. Functional immunoregulatory T-cell abnormalities in cystic fibrosis patients. J. Clin. Immunol. 9 (4), 287–295 (1989).
213. Raga S, Julia MR, Crespi C et al. γδ T lymphocytes from cystic fibrosis patients and healthy donors are high TNF-α and IFN-γ-producers in response to Pseudomonas aeruginosa. Respir. Res. 4, 9 (2003).
214. Kersten CM, McCluskey RT, Boyle LA, Kurnick JT. Escherichia coli and Pseudomonas aeruginosa induce expansion of Vδ2 cells in adult peripheral blood, but of Vδ1 cells in cord blood. J. Immunol. 157 (4), 1613–1619 (1996).
215. Hoiby N, Flensborg EW, Beck B et al. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand. J. Respir. Dis. 58 (2), 65–79 (1977).
216. Cowan RG, Winnie GB. Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis. J. Clin. Immunol. 13 (5), 359–370 (1993).
217. Garside JP, Kerrin DP, Brownlee KG et al. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr. Pulmonol. 39 (2), 135–140 (2005).
218. Johansen HK, Norregaard L, Gotzsche PC et al. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success? – a 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr. Pulmonol. 37 (5), 427–432 (2004).
219. Kikuchi T, Hackett NR, Crystal RG. Cross-strain protection against clinical and laboratory strains of Pseudomonas aeruginosa mediated by dendritic cells genetically modified to express CD40 ligand and pulsed with specific strains of Pseudomonas aeruginosa. Hum. Gene Ther. 12 (10), 1251–1263 (2001).
220. Pier G. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev. Vaccines 4 (5), 645–656 (2005).
221. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr. Infect. Dis. J. 26 (1), 8–12 (2007).
222. Doring G, Conway SP, Heijerman HG et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16 (4), 749–767 (2000).
223. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338 (8769), 725–726 (1991).
224. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23 (5), 330–335 (1997).
225. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J. Cyst. Fibros. 4 (Suppl. 2) 49–54 (2005).
226. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358 (9286), 983–984 (2001).
227. Wiesemann HG, Steinkamp G, Ratjen F et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr. Pulmonol. 25 (2), 88–92 (1998).
228. Gibson RL, Emerson J, McNamara S et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 167 (6), 841–849 (2003).
229. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332 (13), 848–854 (1995).
230. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am. Rev. Respir. Dis. 141 (1), 186–192 (1990).
231. Konstan MW, Hoppel CL, Chai BL, Davis PB. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J. Pediatr. 118 (6), 956–964 (1991).
232. Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N. Engl. J. Med. 338 (1), 65–66 (1998).
233. Bell EA, Grothe R, Zivkovich V, Foote JM, Wellendorf J. Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. Ann. Pharmacother. 33 (6), 693–696 (1999).
234. Fennell PB, Quante J, Wilson K et al. Use of high-dose ibuprofen in a pediatric cystic fibrosis center. J. Cyst. Fibros. 6 (2), 153–158 (2007).
235. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst. Rev. 2, CD000407 (2000).
236. Fernandes PB, Kim C, Cundy KR, Haung NN. Antibodies to cell envelope proteins of Pseudomonas aeruginosa in cystic fibrosis patients. Infect. Immun. 33 (2), 527–532 (1981).
237. Wood RE, Pennington JE, Reynolds HY. Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients. Pediatr. Infect. Dis. 2 (5), 367–369 (1983).
238. Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis-three year results. Arch. Dis. Child. 59 (12), 1131–1134 (1984).
239. Zuercher AW, Horn MP, Que JU et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. 47 (2), 302–308 (2006).
240. Zuercher AW, Imboden MA, Jampen S et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin. Exp. Immunol. 143 (1), 132–138 (2006).
241. DiGiandomenico A, Rao J, Harcher K et al. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. Natl Acad. Sci. USA 104 (11), 4624–4629 (2007).
242. Imamura Y, Yanagihara K, Fukuda Y et al. Effect of anti-PcrV antibody in murine chronic airway Pseudomonas aeruginosa infection model. Eur. Respir. J. 29 (5), 965–968 (2007).